Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Double-Blind Placebo-Controlled Study Comparing the Combination of 15% SP-303 Gel With Acyclovir Versus Acyclovir Alone for the Treatment of Recurrent Herpes Simplex Virus (HSV) Infections in Subjects With Acquired Immunodeficiency Syndrome (AIDS)

This study has been completed.
Information provided by:
NIH AIDS Clinical Trials Information Service Identifier:
First received: November 2, 1999
Last updated: June 23, 2005
Last verified: February 1998
To evaluate the safety of topically applied SP-303 gel and to compare the efficacy of SP-303 gel in combination with acyclovir, relative to acyclovir alone, for the treatment of recurrent Herpes Simplex Virus (HSV) 1 and 2 infections, affecting the genital, perianal and neighboring areas, in patients with AIDS.

Condition Intervention
Herpes Simplex
HIV Infections
Drug: Crofelemer
Drug: Acyclovir

Study Type: Interventional
Study Design: Masking: Double-Blind
Primary Purpose: Treatment
Official Title: Double-Blind Placebo-Controlled Study Comparing the Combination of 15% SP-303 Gel With Acyclovir Versus Acyclovir Alone for the Treatment of Recurrent Herpes Simplex Virus (HSV) Infections in Subjects With Acquired Immunodeficiency Syndrome (AIDS)

Resource links provided by NLM:

Further study details as provided by NIH AIDS Clinical Trials Information Service:

Estimated Enrollment: 400
Detailed Description:
This trial is a double-blind, multicenter, placebo-controlled clinical trial. Participants are randomized to topical 15% SP-303 gel and oral acyclovir or to matching topical placebo gel and oral acyclovir. At presentation, patients are stratified by total lesion area within each treatment group. SP-303 or matching placebo is topically applied three times a day until all lesions are reepithelialized or for 14 days, whichever occurs earlier. Acyclovir is administered by mouth each day, three times a day, until all lesions are reepithelialized or for 14 days, whichever occurs earlier. Patients are evaluated for lesion healing and adverse events 3 times per week during the treatment period. The primary efficacy endpoint will be complete lesion healing and the primary analysis will be time to complete healing.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria

Patients must have:

  • AIDS, according to the CDC criteria.
  • Documented recurrent (at least 1 prior episode) perineal (genital, perianal and neighboring areas) mucocutaneous herpes simplex virus (HSV) types 1 or 2 infection in the active phase.
  • Duration of current episode of recurrent HSV lesions of 3 days or less.
  • Ability to read and write, must be intellectually competent, and able to understand the purposes and risks of the study.

Exclusion Criteria

Co-existing Condition:

Patients with the following symptoms and conditions are excluded:

  • Active internal anal or rectal herpes.
  • Inability to comply with protocol.
  • Impaired renal function.

Patients with the following prior conditions are excluded:

  • Prior episode of recurrent genital herpes infection with documented clinical failure of acyclovir as a treatment regimen.
  • Uncompensated hepatic, cardiac, or renal failure within 1 month of the study.
  • History of hypersensitivity to acyclovir.
  • Previous enrollment in this study.

    1. Treatment with another medication (topical, oral, or intravenous) with known anti-HSV activity within the past 5 days.

  • Systemic immunomodulatory therapy within 30 days prior to study.
  • Previous treatment with SP-303.


Unchanged antiretroviral therapy for the 2 weeks prior to study.

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00002186

  Hide Study Locations
United States, Alabama
Sorra Research Ctr Inc / Med Forum
Birmingham, Alabama, United States, 35203
United States, Arizona
Hill Top Research Ltd
Scottsdale, Arizona, United States, 85251
Arizona Clinical Research Ctr Inc
Tucson, Arizona, United States, 85712
United States, California
Dermatology SVC - VAMC
Long Beach, California, United States, 90822
King - Drew Med Ctr / Dept of Dermatology
Los Angeles, California, United States, 90059
Summit Med Ctr / Adult Immunology Clinic
Oakland, California, United States, 94609
ViRx Inc
Palm Springs, California, United States, 92262
ViRx Inc
San Francisco, California, United States, 94109
Conant Med Ctr
San Francisco, California, United States, 94117
Olive View Med Ctr
Sylmar, California, United States, 91342
United States, District of Columbia
Novum Inc
Washington, District of Columbia, United States, 20037
United States, Florida
IDC Research Initiative
Altamonte Springs, Florida, United States, 32701
Gary Richmond MD
Fort Lauderdale, Florida, United States, 33316
Dr Robert Schwartz
Fort Myers, Florida, United States, 33901
Infectious Disease Research Institute Inc
Tampa, Florida, United States, 33614
Treasure Coast Infectious Disease Consultants
Vero Beach, Florida, United States, 32960
United States, Illinois
Veterans Affairs Med Ctr of North Chicago
Chicago, Illinois, United States, 60064
United States, Maryland
Johns Hopkins Univ / Division of Infectious Disease
Baltimore, Maryland, United States, 21205
Saint Agnes Healthcare / Dept of Surgery
Baltimore, Maryland, United States, 21229
United States, Massachusetts
Massachusetts Gen Hosp - Warren 505
Boston, Massachusetts, United States, 02114
United States, Minnesota
Medicine / Infectious Diseases
Minneapolis, Minnesota, United States, 55455
United States, New York
AIDS Ctr / Saint Vincents Hosp and Med Ctr
New York, New York, United States, 10011
New York Univ Med Ctr
New York, New York, United States, 10016
Mount Sinai Med Ctr
New York, New York, United States, 10029
Columbia Presbyterian Med Ctr
New York, New York, United States, 10032
United States, Pennsylvania
Paddington Testing Co Inc
Philadelphia, Pennsylvania, United States, 19103
United States, Texas
Austin Infectious Disease Consultants
Austin, Texas, United States, 78705
N Texas Ctr for AIDS & Clin Rsch
Dallas, Texas, United States, 75219
Division of Infectious Diseases / Univ of Texas - Houston
Houston, Texas, United States, 77030
United States, Virginia
Dr Robert Holman
Arlington, Virginia, United States, 22205
United States, Washington
Novum Inc
Seattle, Washington, United States, 98122
Univ of Washington Virology Research Clinic
Seattle, Washington, United States, 98122
Puerto Rico
Hosp Regional de Ponce - Area Vieja
Ponce, Puerto Rico, 00731
San Juan AIDS Program
Santurce, Puerto Rico, 00908
Sponsors and Collaborators
Shaman Pharmaceuticals
  More Information Identifier: NCT00002186     History of Changes
Other Study ID Numbers: 270A
Study First Received: November 2, 1999
Last Updated: June 23, 2005

Keywords provided by NIH AIDS Clinical Trials Information Service:
AIDS-Related Opportunistic Infections
Herpes Simplex
Drug Therapy, Combination
Antiviral Agents
SP 303

Additional relevant MeSH terms:
Communicable Diseases
HIV Infections
Immunologic Deficiency Syndromes
Acquired Immunodeficiency Syndrome
Herpes Simplex
Lentivirus Infections
Retroviridae Infections
RNA Virus Infections
Virus Diseases
Sexually Transmitted Diseases, Viral
Sexually Transmitted Diseases
Immune System Diseases
Slow Virus Diseases
Herpesviridae Infections
DNA Virus Infections
Skin Diseases, Viral
Skin Diseases, Infectious
Skin Diseases
Antiviral Agents
Anti-Infective Agents processed this record on April 25, 2017